Showing results (341-350 of 592) with videos related to

Sort By:
Pageof 60
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupMichel Marty, Francesco Cognetti, Dominique Maraninchi, et al.
The Journal of Molecular Diagnostics : JMD|February 9, 2008
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistryFerenc Pinter, Judit Papay, Andrea Almasi, et al.
Breast Cancer Research and Treatment|November 23, 2017
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trialJoyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke, et al.
Breast Cancer Research and Treatment|February 25, 2016
Whole exome sequencing of rare aggressive breast cancer histologiesMaria Vittoria Dieci, Veronika Smutná, Véronique Scott, et al.
The Oncologist|July 4, 2020
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast CancerFederica Miglietta, Maria Vittoria Dieci, Vassilena Tsvetkova, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2019
Pembrolizumab as first-line treatment for metastatic uveal melanomaErnesto Rossi, Monica Maria Pagliara, Daniela Orteschi, et al.
Frontiers in Oncology|September 27, 2021
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic AdenocarcinomaIlaria Trestini, Luisa Carbognin, Umberto Peretti, et al.
ESMO Open|May 20, 2020
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcomeIlaria Trestini, Isabella Sperduti, Marco Sposito, et al.
Virchows Archiv : an International Journal of Pathology|February 2, 2018
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigmGiuseppe Pelosi, Fabrizio Bianchi, Elisa Dama, et al.
Expert Opinion on Drug Discovery|October 4, 2013
Advances towards the design and development of personalized non-small-cell lung cancer drug therapySabrina Vari, Sara Pilotto, Marcello Maugeri-Saccà, et al.
Pageof 60